Swiss drugmaker Santhera’s shares plunged nearly 60 percent after a European panel recommended against approving one of the company’s drugs to be used in patients with Duchenne muscular dystrophy (DMD).

GlaxoSmithKline said a European Medicines Agency (EMA) panel recommended for approval the company’s three-in-one inhaled lung drug.